Royalty Pharma plc
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Royalty Pharma plc (Nasdaq: RPRX) operates as the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry; the company acquires royalties on sales of approved and development-stage biopharmaceutical products from originators including pharmaceutical companies, biotechnology firms, universities and research institutions. Its portfolio encompasses royalties on more than 35 marketed products and over a dozen pipeline candidates targeting diseases such as cystic fibrosis (Kalydeco, Orkambi, Symdeko, Trikafta from Vertex Pharmaceuticals), multiple sclerosis (Tysabri from Biogen, frexalimab from Sanofi), blood cancers (Imbruvica from AbbVie and Johnson & Johnson, IDHIFA from Bristol Myers Squibb), prostate cancer (Xtandi from Astellas and Pfizer, Erleada from Johnson & Johnson), ATTR amyloidosis (Amvuttra from Alnylam), spinal muscular atrophy (Evrysdi from Roche, Spinraza from Biogen), migraine (Emgality from Lilly, Nurtec ODT and Zavzpret from Pfizer), diabetes (Januvia and Onglyza from Merck, Soliqua from Sanofi), inflammatory conditions (Tremfya from Johnson & Johnson, Cimzia from UCB, Entyvio from Takeda), respiratory diseases (Trelegy Ellipta from GSK, Airsupra from AstraZeneca), and other areas including schizophrenia (Cobenfy from Bristol Myers Squibb, TEV-'749 from Teva), growth hormone deficiency (Skytrofa from Ascendis Pharma), bladder cancer (Adstiladrin from Ferring), hypoparathyroidism (Yorvipath from Ascendis), low-grade glioma (Voranigo from Servier), chronic graft-versus-host disease (Niktimvo from Syndax and Incyte), and myelodysplastic syndromes (Rytelo from Geron); pipeline royalties include obexelimab for immunoglobulin G4-related disease from Zenas BioPharma, Imdelltra for small cell lung cancer from Amgen, daraxonrasib for RAS mutant pancreatic cancer from Revolution Medicines, litifilimab for lupus from Biogen, and others such as aficamten, ampreloxetine, ecopipam, olpasiran, pelacarsen, pelabresib, seltorexant, trontinemab, and tulmimetostat. Royalty Pharma conducts its royalty acquisition and funding activities principally in the United States and Europe, with global exposure through its diverse portfolio of international product sales. Founded in 1996 by Pablo Legorreta and Rory B. Riggs and headquartered in New York, New York, the company went public in 2020. Recent developments include the acquisition of a royalty interest in Alnylam's Amvuttra from Blackstone Life Sciences for $310 million in November 2025; a royalty on Amgen's Imdelltra for small cell lung cancer acquired for up to $950 million in 2025; a $2 billion funding arrangement with Revolution Medicines including royalties on daraxonrasib in June 2025; royalties on Rytelo, Niktimvo, Yorvipath, and Voranigo added in 2024; and earlier 2023-2025 transactions such as royalties on obexelimab, litifilimab, Evrysdi, Skytrofa, Adstiladrin, and Cobenfy, reflecting ongoing expansion into oncology, neurology, rare diseases, and synthetic royalty structures.
Company News
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Royalty Pharma to present at upcoming investor conferences
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating
Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Royalty Pharma Q2 Earnings Call Highlights
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma reports second quarter 2026 results
Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release